{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T07:37:12Z","timestamp":1774597032737,"version":"3.50.1"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Drug Saf. Regul."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Recent studies suggest an association between fetal topiramate exposure and an increased risk of neurodevelopmental disorders (NDD), such as autism spectrum disorders (ASD), intellectual disability (ID) and attention deficit hyperkinetic disorder (ADHD). This systematic review aimed to evaluate the evidence for such an association.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic literature search was conducted in Medline, Cochrane, and Embase on 16 December 2024, with automatic updates running until submission. Articles were examined if they included any number of offsprings of persons with epilepsy of childbearing potential (PWECP) exposed to topiramate during pregnancy. The main comparison was offspring of pregnant people without epilepsy and no antiseizure medication use, or alternatively antiseizure medication apart from topiramate. The search was limited to English language articles 2014\u20132024. The study followed PRISMA guidelines for reporting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>14 studies were included. The number of topiramate-exposed children ranged from 2 to 1,000. Most studies had a small group exposed to topiramate, and a large control group. Seven studies found a relationship between NDD outcomes and topiramate, three studies found no increased risk, and four studies were inconclusive. However, the risk seems mainly to be increased relative to no ASM use, and in many studies the risk was similar for lamotrigine and seemed lower than for valproate. Methodological approaches varied. Eleven studies were considered to be of good or fair quality, whereas three studies were considered to be of poor quality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This systematic review shows that topiramate prescribing requires caution in PWECP and that topiramate use during pregnancy warrants special attention to the neurodevelopment of the child. The risk seems to be increased relative to no ASM use, is not necessarily higher than the risk for lamotrigine, and lower than the risk of valproate.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fdsfr.2026.1761506","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T06:40:34Z","timestamp":1774593634000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk of neurodevelopmental disorders after fetal topiramate exposure: a systematic review"],"prefix":"10.3389","volume":"6","author":[{"given":"Renate Eikev\u00e5g","family":"Lund\u00f8y","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Bergen","place":["Bergen, Norway"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anniken","family":"Sigvathsen","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Bergen","place":["Bergen, Norway"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marte-Helene","family":"Bj\u00f8rk","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, University of Bergen","place":["Bergen, Norway"]},{"name":"Neurological Department, Haukeland University Hospital","place":["Bergen, Norway"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils Erik","family":"Gilhus","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, University of Bergen","place":["Bergen, Norway"]},{"name":"Neurological Department, Haukeland University Hospital","place":["Bergen, Norway"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny Linnea Victoria","family":"Lindroos","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, University of Bergen","place":["Bergen, Norway"]},{"name":"Neurological Department, Haukeland University Hospital","place":["Bergen, Norway"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"37 EP","DOI":"10.1016\/j.ejpn.2014.09.006","article-title":"Pregnancy and neurodevelopmental outcomes with in-utero antiepileptic agent exposure. A pilot study","volume":"19","author":"Arkilo","year":"2015","journal-title":"Eur. J. Paediatr. Neurology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1136\/jnnp-2018-318386","article-title":"In utero exposure to antiepileptic drugs is associated with learning disabilities among offspring","volume":"89","author":"Bech","year":"2018","journal-title":"J. Neurology, Neurosurg. and Psychiatry"},{"key":"B3","doi-asserted-by":"publisher","first-page":"772 EP","DOI":"10.1001\/jamaneurol.2022.1269","article-title":"Association of prenatal exposure to antiseizure medication with risk of autism and intellectual disability","volume":"79","author":"Bjork","year":"2022","journal-title":"JAMA Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e034829","DOI":"10.1136\/bmjopen-2019-034829","article-title":"Risk of early neurodevelopmental outcomes associated with prenatal exposure to the antiepileptic drugs Most commonly used during pregnancy: a French nationwide population-based cohort study","volume":"10","author":"Bloti\u00e8re","year":"2020","journal-title":"BMJ Open"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1943 EP","DOI":"10.1212\/wnl.0000000000003157","article-title":"Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate","volume":"87","author":"Bromley","year":"2016","journal-title":"Neurology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1111\/epi.17892","article-title":"Topiramate ban in women of childbearing potential with idiopathic generalized epilepsy: does effectiveness offset the teratogenic risks?","volume":"65","author":"Cerulli Irelli","year":"2024","journal-title":"Epilepsia"},{"key":"B7","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/pds.5035","article-title":"Prevalence trends and individual patterns of antiepileptic drug use in pregnancy 2006-2016: a study in the five nordic countries, United States, and Australia","volume":"29","author":"Cohen","year":"2020","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B8","doi-asserted-by":"publisher","first-page":"568 EP","DOI":"10.1001\/jamaneurol.2023.0674","article-title":"Prenatal exposure to antiseizure medication and incidence of Childhood- and adolescence-onset psychiatric disorders","volume":"80","author":"Dreier","year":"2023","journal-title":"JAMA Neurol."},{"key":"B9","unstructured":"Topiramate \u2013 referral\n          \n          \n            \n              Ema\n              E. M. A.\n            \n          \n          \n          2023"},{"key":"B10","volume-title":"PRISMA2020: an R package and shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis campbell systematic reviews","author":"Haddaway","year":"2022"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1069 EP","DOI":"10.1056\/nejmoa2309359","article-title":"Risk of autism after prenatal topiramate, valproate, or lamotrigine exposure","volume":"390","author":"Hernandez-Diaz","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B33","first-page":"300","article-title":"The environment and disease: Association or causation?","volume":"58","author":"Hill","year":"1965","journal-title":"Proc. R. Soc. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e209175","DOI":"10.1212\/wnl.0000000000209175","article-title":"Neurodevelopmental and functional outcomes following in utero exposure to antiseizure medication","volume":"102","author":"Honybun","year":"2024","journal-title":"Neurology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e074630","DOI":"10.1136\/bmj-2022-074630","article-title":"Management of epilepsy during pregnancy and lactation","volume":"382","author":"Hope","year":"2023","journal-title":"BMJ"},{"key":"B14","doi-asserted-by":"publisher","first-page":"56 EP","DOI":"10.1016\/j.seizure.2023.01.008","article-title":"Adaptive behaviour in children exposed to topiramate in the womb: an observational cohort study","volume":"105","author":"Knight","year":"2023","journal-title":"Seizure"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53813-1","article-title":"Antiseizure medication use during pregnancy and children's neurodevelopmental outcomes - PubMed","volume":"15","author":"Madley-Dowd","year":"2024","journal-title":"Nat. Communications"},{"key":"B16","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/S1474-4422(23)00199-0","article-title":"Cognitive outcomes at age 3 years in children with fetal exposure to antiseizure medications (MONEAD study) in the USA: a prospective, observational cohort study","volume":"22","author":"Meador","year":"2023","journal-title":"Lancet Neurology"},{"key":"B17","volume-title":"Microsoft 365 copilot","year":"2025"},{"key":"B18","unstructured":"LUNG, AND BLOOD INSTITUTE (NHLBI)\n          \n          \n            \n              Nhlbi\n              N. H.\n            \n          \n          \n          2025"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e811","DOI":"10.1212\/WNL.0000000000006073","article-title":"Verbal abilities in children of mothers with epilepsy","volume":"91","author":"Nilsen Husebye","year":"2018","journal-title":"Neurology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/ene.14140","article-title":"Language impairment in children aged 5 and 8 years after antiepileptic drug exposure in utero - the Norwegian mother and child cohort study","volume":"27","author":"Nilsen Husebye","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"B21","volume-title":"ChatGPT. OpenAI","year":"2025"},{"key":"B22","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014A web and Mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e209279","DOI":"10.1212\/wnl.0000000000209279","article-title":"Teratogenesis, perinatal, and neurodevelopmental outcomes after in utero exposure to antiseizure medication","volume":"102","author":"Pack","year":"2024","journal-title":"Neurology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"Page","year":"2021","journal-title":"PRISMA 2020 Statement An Updated Guideline Reporting Systematic Reviews. Syst. Rev."},{"key":"B25","doi-asserted-by":"crossref","DOI":"10.1101\/2024.03.26.24304895","article-title":"United Kingdom national register study of anti-epileptic medications: suspected foetal congenital and pregnancy-associated side effects","author":"Phillips","year":"2024"},{"key":"B26","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.reprotox.2012.05.038","article-title":"Preliminary findings of the developmental effects of in utero exposure to topiramate","volume":"34","author":"Rihtman","year":"2012","journal-title":"Reprod. Toxicol."},{"key":"B32","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/10408444.2024.2368552","article-title":"Mechanisms of neurodevelopmental toxicity of topiramate","volume":"54","author":"Steele","year":"2024","journal-title":"Crit. Rev. Toxicol."},{"key":"B27","volume-title":"EndNote","author":"Software","year":"2023"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e017248","DOI":"10.1136\/bmjopen-2017-017248","article-title":"Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis","volume":"7","author":"Veroniki","year":"2017","journal-title":"BMJ Open"},{"key":"B29","unstructured":"International classification of diseases 10th revision (ICD-10): F80-F89 - Pervasive and specific developmental disorders\n          \n          \n          2019"},{"key":"B30","volume-title":"Epilepsy: fact sheet","year":"2024"},{"key":"B31","volume-title":"International classification of diseases 11th revision (ICD-11): 06 mental, behavioural or neurodevelopmental disorders","year":"2025"}],"container-title":["Frontiers in Drug Safety and Regulation"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fdsfr.2026.1761506\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T06:40:45Z","timestamp":1774593645000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fdsfr.2026.1761506\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":33,"alternative-id":["10.3389\/fdsfr.2026.1761506"],"URL":"https:\/\/doi.org\/10.3389\/fdsfr.2026.1761506","relation":{},"ISSN":["2674-0869"],"issn-type":[{"value":"2674-0869","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"article-number":"1761506"}}